N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
Phase 2 N=109 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Inflammation and Pain Following Ocular Surgery
Primary: Absence of Anterior Chamber Cells at Day 15 (Visit 5) — 10; 12; 11; 27 Participants — p=0.4543
Phase 4 N=11 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
Phase 4 N=50 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Allergic Conjunctivitis
Primary: Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1 — 3.12; 3.02 units on a scale
Phase 2 N=153 OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Inflammation Corneal · Pain, Postoperative
Primary: Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0') — 26; 34; 10 participants
Phase 2 N=37 A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
Post Surgical Ocular Inflammation
Primary: Assessment of Both Systemic and Ocular Adverse Events — 0; 3; 0; 0 Number of TEAE
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 19; 13 participants — p=0.0014
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
N/A N=10 Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Sjogren's Disease
Primary: Ocular Surface Temperature of Both Eyes — 33.95; 34.3; 33.93; 33.95 degrees celcius
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 18; 7 participants — p=<0.0001
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 4 N=36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Baseline (Day 0) — 2.53; 3.08; 2.61; 2.5 units on a scale
Phase 2 N=60 Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of Study Eye — 6; 3 Participants
N/A N=50 Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Cataract · Retinal Edema · Inflammation
Primary: Treatment of Inflammation Associated With Cataract Surgery — 0.01; 0.01 units on a scale
Phase 2 N=289 Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Dry Eye Disease
Primary: Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 Weeks — 78.3; 76.8; -1.1; -1.7 units on a scale
Phase 3 N=178 Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Cataract
Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065
Phase 4 N=5 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Uveitis · Anterior Uveitis · Intermediate Uveitis
Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
Phase 2 N=415 Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
Cataract · Inflammation
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 35; 19; 15; 47 Participants
Phase 3 N=241 A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation Eye Pain · Postoperative Cataract
Primary: Absence of Anterior Chamber Cells at Visit 6. — 57.2; 24.0 percentage of study eyes — p=<0.0001
Phase 2 N=256 Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
Phase 2 N=31 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
Uveitis
Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…
N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Phase 2 N=5 Topical Interferon Gamma for Macular Edema Secondary to Uveitis
Anterior Uveitis · Uveitis
Primary: Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline — -38.60 µm
Phase 4 N=20 Study of the Effectiveness of Ozurdex for the Control of Uveitis
Uveitis, Intermediate · Uveitis, Posterior
Primary: Number of Participants With Absence of Intraocular Inflammation at 6 Months — 12 Participants
Phase 3 N=241 OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Number of Participants With an Absence of Anterior Chamber Inflammation — 63; 25 participants